Who Paid My Doc
Abecma
Biological Oncology
NDC 59572-515-01
General payments
$680,851
Research payments
$33,965,404
Through program year 2025, $680,851 in general payments and $33,965,404 in research payments were reported against Abecma (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $93,148 | 183 |
| 2025 | Research | $5,737,392 | 35 |
| 2024 | General | $190,574 | 395 |
| 2024 | Research | $5,237,662 | 68 |
| 2023 | General | $24,049 | 191 |
| 2023 | Research | $7,668,504 | 52 |
| 2022 | General | $148,517 | 125 |
| 2022 | Research | $6,594,788 | 80 |
| 2021 | General | $224,563 | 965 |
| 2021 | Research | $8,727,058 | 88 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 20 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 17 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
1,859 general · 323 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.